Detection of Cannabinoid Receptors CB1 and CB2 Within Basal Ganglia Output Neurons in Macaques: Changes Following Experimental Parkinsonism

Overview

Journal Brain Struct Funct

Specialty Neurology

Date 2014 Jun 29

PMID 24972960

Citations 50

Authors

Salvador Sierra

Natasha Luquin

Alberto J Rico

Virginia Gomez-Bautista

Elvira Roda

Iria G Dopeso-Reyes

Alfonso Vazquez

Eva Martinez-Pinilla

Jose L Labandeira-Garcia

Rafael Franco

Jose L Lanciego

Affiliations

Soon will be listed here.

Abstract

Although type 1 cannabinoid receptors (CB1Rs) are expressed abundantly throughout the brain, the presence of type 2 cannabinoid receptors (CB2Rs) in neurons is still somewhat controversial. Taking advantage of newly designed CB1R and CB2R mRNA riboprobes, we demonstrate by PCR and in situ hybridization that transcripts for both cannabinoid receptors are present within labeled pallidothalamic-projecting neurons of control and MPTP-treated macaques, whereas the expression is markedly reduced in dyskinetic animals. Moreover, an in situ proximity ligation assay was used to qualitatively assess the presence of CB1Rs and CB2Rs, as well as CB1R-CB2R heteromers within basal ganglia output neurons in all animal groups (control, parkinsonian and dyskinetic macaques). A marked reduction in the number of CB1Rs, CB2Rs and CB1R-CB2R heteromers was found in dyskinetic animals, mimicking the observed reduction in CB1R and CB2R mRNA expression levels. The fact that chronic levodopa treatment disrupted CB1R-CB2R heteromeric complexes should be taken into consideration when designing new drugs acting on cannabinoid receptor heteromers.

Citing Articles

Cannabinoids: Role in Neurological Diseases and Psychiatric Disorders.

Kumar U Int J Mol Sci. 2025; 26(1.

PMID: 39796008 PMC: 11720483. DOI: 10.3390/ijms26010152.

Cannabinoid regulation of angiotensin II-induced calcium signaling in striatal neurons.

Rivas-Santisteban R, Munoz A, Lillo J, Raich I, Rodriguez-Perez A, Navarro G NPJ Parkinsons Dis. 2024; 10(1):220.

PMID: 39548112 PMC: 11568119. DOI: 10.1038/s41531-024-00827-7.

CBD's potential impact on Parkinson's disease: An updated overview.

Hafida E, Rachid S, Halima G, Najib K Open Med (Wars). 2024; 19(1):20241075.

PMID: 39479465 PMC: 11524397. DOI: 10.1515/med-2024-1075.

The Use of Compounds Derived from in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders.

Stasilowicz-Krzemien A, Nogalska W, Maszewska Z, Maleszka M, Dobron M, Szary A Int J Mol Sci. 2024; 25(11).

PMID: 38891938 PMC: 11171823. DOI: 10.3390/ijms25115749.

Advice to People with Parkinson's in My Clinic: Cannabis.

de Freitas M, Fox S J Parkinsons Dis. 2024; 14(4):873-881.

PMID: 38759024 PMC: 11191450. DOI: 10.3233/JPD-230358.

References

Grimsey N, Goodfellow C, Scotter E, Dowie M, Glass M, Graham E . Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal!. J Neurosci Methods. 2008; 171(1):78-86. DOI: 10.1016/j.jneumeth.2008.02.014. View

Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A . Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci. 2003; 18(6):1607-14. DOI: 10.1046/j.1460-9568.2003.02896.x. View

Galiegue S, MARY S, Marchand J, Dussossoy D, Carriere D, Carayon P . Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995; 232(1):54-61. DOI: 10.1111/j.1432-1033.1995.tb20780.x. View

Maresz K, Carrier E, Ponomarev E, Hillard C, Dittel B . Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem. 2005; 95(2):437-45. DOI: 10.1111/j.1471-4159.2005.03380.x. View

Mailleux P, Vanderhaeghen J . Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 1992; 48(3):655-68. DOI: 10.1016/0306-4522(92)90409-u. View

Ferre S, Baler R, Bouvier M, Caron M, Devi L, Durroux T . Building a new conceptual framework for receptor heteromers. Nat Chem Biol. 2009; 5(3):131-4. PMC: 2681085. DOI: 10.1038/nchembio0309-131. View

Lastres-Becker I, Cebeira M, de Ceballos M, Zeng B, Jenner P, Ramos J . Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci. 2002; 14(11):1827-32. DOI: 10.1046/j.0953-816x.2001.01812.x. View

Zeng B, Dass B, Owen A, Rose S, Cannizzaro C, Tel B . Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci Lett. 2000; 276(2):71-4. DOI: 10.1016/s0304-3940(99)00762-4. View

Hohmann A, Herkenham M . Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse. 2000; 37(1):71-80. DOI: 10.1002/(SICI)1098-2396(200007)37:1<71::AID-SYN8>3.0.CO;2-K. View

10.

Ashton J, Friberg D, Darlington C, Smith P . Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett. 2005; 396(2):113-6. DOI: 10.1016/j.neulet.2005.11.038. View

11.

Segovia G, Mora F, Crossman A, Brotchie J . Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Mov Disord. 2003; 18(2):138-49. DOI: 10.1002/mds.10312. View

12.

Moldrich G, Wenger T . Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides. 2000; 21(11):1735-42. DOI: 10.1016/s0196-9781(00)00324-7. View

13.

Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z . The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett. 1995; 375(1-2):143-7. DOI: 10.1016/0014-5793(95)01207-u. View

14.

Rico A, Barroso-Chinea P, Conte-Perales L, Roda E, Gomez-Bautista V, Gendive M . A direct projection from the subthalamic nucleus to the ventral thalamus in monkeys. Neurobiol Dis. 2010; 39(3):381-92. DOI: 10.1016/j.nbd.2010.05.004. View

15.

Reguero L, Puente N, Elezgarai I, Mendizabal-Zubiaga J, Canduela M, Buceta I . GABAergic and cortical and subcortical glutamatergic axon terminals contain CB1 cannabinoid receptors in the ventromedial nucleus of the hypothalamus. PLoS One. 2011; 6(10):e26167. PMC: 3191179. DOI: 10.1371/journal.pone.0026167. View

16.

Sossin W, DesGroseillers L . Intracellular trafficking of RNA in neurons. Traffic. 2006; 7(12):1581-9. DOI: 10.1111/j.1600-0854.2006.00500.x. View

17.

den Boon F, Chameau P, Schaafsma-Zhao Q, van Aken W, Bari M, Oddi S . Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proc Natl Acad Sci U S A. 2012; 109(9):3534-9. PMC: 3295302. DOI: 10.1073/pnas.1118167109. View

18.

Gilgun-Sherki Y, Melamed E, Mechoulam R, Offen D . The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacol Toxicol. 2003; 93(2):66-70. DOI: 10.1034/j.1600-0773.2003.930202.x. View

19.

Morgese M, Cassano T, Gaetani S, Macheda T, Laconca L, Dipasquale P . Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochem Int. 2008; 54(1):56-64. PMC: 2657321. DOI: 10.1016/j.neuint.2008.10.007. View

20.

Hasbi A, Fan T, Alijaniaram M, Nguyen T, Perreault M, ODowd B . Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci U S A. 2009; 106(50):21377-82. PMC: 2795506. DOI: 10.1073/pnas.0903676106. View